BR112017004544A2 - insulina de cadeia simples, composição farmacêutica e método para tratar diabetes mellitus - Google Patents
insulina de cadeia simples, composição farmacêutica e método para tratar diabetes mellitusInfo
- Publication number
- BR112017004544A2 BR112017004544A2 BR112017004544A BR112017004544A BR112017004544A2 BR 112017004544 A2 BR112017004544 A2 BR 112017004544A2 BR 112017004544 A BR112017004544 A BR 112017004544A BR 112017004544 A BR112017004544 A BR 112017004544A BR 112017004544 A2 BR112017004544 A2 BR 112017004544A2
- Authority
- BR
- Brazil
- Prior art keywords
- domain
- residues
- amino acid
- pharmaceutical composition
- chain insulin
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
- 102000004877 Insulin Human genes 0.000 title abstract 3
- 108090001061 Insulin Proteins 0.000 title abstract 3
- 229940125396 insulin Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060167P | 2014-10-06 | 2014-10-06 | |
| PCT/US2015/054263 WO2016057529A2 (en) | 2014-10-06 | 2015-10-06 | Biphasic single-chain insulin analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017004544A2 true BR112017004544A2 (pt) | 2018-01-23 |
Family
ID=55653938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017004544A BR112017004544A2 (pt) | 2014-10-06 | 2015-10-06 | insulina de cadeia simples, composição farmacêutica e método para tratar diabetes mellitus |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10392429B2 (enExample) |
| EP (1) | EP3204410B1 (enExample) |
| JP (1) | JP6829928B2 (enExample) |
| KR (1) | KR102569743B1 (enExample) |
| CN (1) | CN107108716A (enExample) |
| AU (1) | AU2015328222B9 (enExample) |
| BR (1) | BR112017004544A2 (enExample) |
| CA (1) | CA2961037A1 (enExample) |
| IL (1) | IL251503A0 (enExample) |
| WO (1) | WO2016057529A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015106269A2 (en) | 2014-01-13 | 2015-07-16 | Thermalin Diabetes, Llc | Rapid action insulin formulations and pharmaceutical delivery systems |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| HK1255634A1 (zh) * | 2015-12-23 | 2019-08-23 | Case Western Reserve University | 超稳胰岛素类似物在聚合物熔体中的包囊 |
| TW201831504A (zh) * | 2016-11-21 | 2018-09-01 | 美國凱斯西方瑞瑟夫大學 | 增強穩定性之速效胰島素類似物 |
| DK4186920T5 (da) * | 2018-06-29 | 2024-07-22 | Akston Biosciences Corp | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse |
| EP3853246A4 (en) * | 2018-09-21 | 2023-01-11 | Case Western Reserve University | Site 2 single-chain insulin analogues |
| WO2020072181A1 (en) * | 2018-10-01 | 2020-04-09 | University Of Houston System | Engineered active single-polypeptide chain insulin analogs |
| US20220002373A1 (en) * | 2018-11-19 | 2022-01-06 | Case Western Reserve University | Single-chain insulin analogues with poly-alanine c-domain sub-segments |
| WO2020236762A2 (en) * | 2019-05-17 | 2020-11-26 | Case Western Reserve University | Variant single-chain insulin analogues |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| US20220280614A1 (en) * | 2019-08-02 | 2022-09-08 | Case Western Reserve University | Premixed Ultra-Stable Single-Chain Insulin Analogue Formulations |
| JP2023532165A (ja) * | 2020-03-02 | 2023-07-27 | サーマリン インク． | 速効型インスリンアナログを含む組成物 |
| US20240043493A1 (en) * | 2020-12-07 | 2024-02-08 | Case Western Reserve University | Acylated single-chain insulin analogues |
| CZ310198B6 (cs) * | 2021-07-07 | 2024-11-13 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Deriváty inzulínu se zvýšenou tepelnou stabilitou |
| JP2024531773A (ja) | 2021-09-20 | 2024-08-29 | キュオン バイオテック アー・ゲー | アルギナーゼ－インスリン融合タンパク質 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| AU616205B2 (en) | 1988-07-20 | 1991-10-24 | Novo Nordisk A/S | Human insulin analogs and preparations containing them |
| US5716927A (en) | 1988-12-23 | 1998-02-10 | Novo Nordisk A/S | Insulin analogs having a modified B-chain |
| DE3844211A1 (de) | 1988-12-29 | 1990-07-05 | Hoechst Ag | Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| DE3936876A1 (de) | 1989-11-06 | 1991-05-23 | Hoechst Ag | Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| DK158390D0 (da) | 1990-07-02 | 1990-07-02 | Novo Nordisk As | Nye peptider |
| US5422339A (en) | 1991-03-19 | 1995-06-06 | Joslin Diabetes Center, Inc. | Peptides having insulin autoantibody but not insulin receptor binding capacity |
| CZ342492A3 (en) | 1991-11-26 | 1993-06-16 | Lilly Co Eli | Derivatives of tri-arginine insulin, process of their preparation and a pharmaceutical composition in which said derivatives are comprised |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| US20030104981A1 (en) | 1995-11-03 | 2003-06-05 | Jelena Mandic | Human insulin analogues |
| DE19652713C2 (de) | 1996-12-18 | 2001-11-22 | Aventis Pharma Gmbh | Verfahren zur Reinigung von Insulin und Insulinderivaten durch Chromatographie an stark saurem Kationenaustauscher |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| TR200001050T2 (tr) | 1997-10-24 | 2000-08-21 | Eli Lilly And Company | Çözünmez insülin bileşimleri |
| CO4970787A1 (es) | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| US7316999B2 (en) | 2000-06-02 | 2008-01-08 | Novo Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
| KR100449454B1 (ko) | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
| AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| EP1545460A4 (en) | 2001-12-20 | 2005-11-16 | Lilly Co Eli | INSULIN MOLECULE WITH TEMPORARY EFFECT |
| US7129211B2 (en) | 2002-03-26 | 2006-10-31 | Council Of Scientific And Industrial Research | Adipocyte Insulin adpinsl with Insulin A and B chains and an effective method of treating type 2 diabetes in a subject using adipocyte insulin |
| WO2003093299A2 (en) | 2002-05-06 | 2003-11-13 | Thomas Jefferson University | Insulin-associated peptides with effects on cerebral health |
| WO2004085472A1 (en) * | 2003-03-27 | 2004-10-07 | Novo Nordisk A/S | Method for making human insulin precursors and human insulin |
| CA2518776A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| DE602004015980D1 (de) | 2003-06-17 | 2008-10-02 | Sembiosys Genetics Inc | Verfahren zur insulinproduktion in pflanzen |
| ES2369895T3 (es) | 2003-12-03 | 2011-12-07 | Novo Nordisk A/S | Insulina monocatenaria. |
| EP1917363B1 (en) * | 2005-08-16 | 2011-06-22 | Novo Nordisk A/S | Method for making mature insulin polypeptides |
| WO2007081824A2 (en) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
| US20090069216A1 (en) | 2006-02-21 | 2009-03-12 | Novo Nordisk A/S | Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof |
| US8192857B2 (en) * | 2006-03-04 | 2012-06-05 | Enerdel, Inc. | Battery assembly and method of forming the same |
| WO2008043033A2 (en) | 2006-10-04 | 2008-04-10 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| US7790677B2 (en) | 2006-12-13 | 2010-09-07 | Elona Biotechnologies | Insulin production methods and pro-insulin constructs |
| AU2009203809B2 (en) | 2008-01-09 | 2013-07-25 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
| WO2009129250A2 (en) | 2008-04-14 | 2009-10-22 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| NZ588857A (en) | 2008-04-22 | 2012-07-27 | Univ Case Western Reserve | Isoform-specific insulin analogue for control blood sugar levels |
| WO2009133099A2 (en) * | 2008-04-28 | 2009-11-05 | Novo Nordisk A/S | Insulin precursors for diabetes treatment |
| MX2011001181A (es) | 2008-07-31 | 2011-04-05 | Univ Case Western Reserve | Insulina estabilizada con halogeno. |
| US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| WO2011028813A2 (en) | 2009-09-01 | 2011-03-10 | Case Western Reserve University | Insulin analogues of enhanced receptor-binding specificity |
| US8399407B2 (en) | 2009-09-17 | 2013-03-19 | Case Western Reserve University | Non-standard insulin analogues |
| MY189079A (en) | 2009-12-11 | 2022-01-25 | Univ Case Western Reserve | Insulin analogues with chlorinated amino acids |
| EA201201164A1 (ru) | 2010-02-22 | 2013-04-30 | Кейз Вестерн Ризев Юнивесити | Препараты на основе аналогов инсулина пролонгированного действия в растворимой и кристаллической формах |
| AU2011268327B2 (en) * | 2010-06-16 | 2016-02-25 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
| KR102163936B1 (ko) * | 2012-11-05 | 2020-10-13 | 케이스 웨스턴 리저브 유니버시티 | 장기-활성 싱글-체인 인슐린 유사체 |
-
2015
- 2015-10-06 JP JP2017518189A patent/JP6829928B2/ja active Active
- 2015-10-06 CA CA2961037A patent/CA2961037A1/en active Pending
- 2015-10-06 BR BR112017004544A patent/BR112017004544A2/pt not_active IP Right Cessation
- 2015-10-06 EP EP15849531.7A patent/EP3204410B1/en active Active
- 2015-10-06 US US15/517,300 patent/US10392429B2/en active Active
- 2015-10-06 KR KR1020177006438A patent/KR102569743B1/ko active Active
- 2015-10-06 WO PCT/US2015/054263 patent/WO2016057529A2/en not_active Ceased
- 2015-10-06 CN CN201580054329.9A patent/CN107108716A/zh active Pending
- 2015-10-06 AU AU2015328222A patent/AU2015328222B9/en active Active
-
2017
- 2017-04-02 IL IL251503A patent/IL251503A0/en unknown
-
2019
- 2019-08-26 US US16/550,973 patent/US11142560B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015328222A1 (en) | 2017-03-16 |
| US20180265560A1 (en) | 2018-09-20 |
| CN107108716A (zh) | 2017-08-29 |
| US11142560B2 (en) | 2021-10-12 |
| AU2015328222B9 (en) | 2020-12-24 |
| EP3204410A2 (en) | 2017-08-16 |
| KR102569743B1 (ko) | 2023-08-23 |
| EP3204410A4 (en) | 2018-03-07 |
| KR20170064533A (ko) | 2017-06-09 |
| WO2016057529A3 (en) | 2016-11-03 |
| JP2017536337A (ja) | 2017-12-07 |
| US20190375814A1 (en) | 2019-12-12 |
| IL251503A0 (en) | 2017-05-29 |
| EP3204410B1 (en) | 2021-01-20 |
| JP6829928B2 (ja) | 2021-02-17 |
| CA2961037A1 (en) | 2016-04-14 |
| US10392429B2 (en) | 2019-08-27 |
| AU2015328222B2 (en) | 2020-08-20 |
| WO2016057529A2 (en) | 2016-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017004544A2 (pt) | insulina de cadeia simples, composição farmacêutica e método para tratar diabetes mellitus | |
| AR110751A1 (es) | Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con proteínas de unión al receptor del péptido inhibidor gástrico (gipr) | |
| BR112019011988A2 (pt) | anticorpo anti-cd73 humana | |
| BR112019011228A2 (pt) | compostos como agonistas do receptor de glp1/glucagon/gip trigonais peptídicos | |
| MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
| CL2018001695A1 (es) | Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1 | |
| BR112019011144A2 (pt) | compostos como agonistas peptídicos de receptor de glp1/glucagon/gip | |
| AR098736A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor del glp-1 / gip (péptido similar al glucagón tipo 1 / polipéptido insulinotrópico dependiente de glucosa) | |
| PE20170471A1 (es) | Polipeptidos receptores formulados y metodos relacionados | |
| DOP2017000248A (es) | PROTEÍNA DE UNIÓN A RGMa Y SU USO | |
| BR112018072915A2 (pt) | peptídeo cíclico isolado e composição farmacêutica | |
| MX380191B (es) | Combinaciones de modalidades para el tratamiento de la diabetes. | |
| MX2016008355A (es) | Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos. | |
| BR112016022465A2 (pt) | agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4 | |
| BRPI0816784A8 (pt) | Fatores neuro-endócrinos para o tratamento de doenças degenerativas | |
| BR112016028520A2 (pt) | métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| BR112017011398A2 (pt) | métodos e composições que usam polipeptídeos variantes de klotho | |
| AR102595A1 (es) | Anticuerpos anti-ang2 y métodos de utilización | |
| MX2016006049A (es) | Mimeticos de calcitonina para tratar enfermedades y trastornos. | |
| CL2017003097A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad celiaca | |
| DOP2012000232A (es) | Proteínas de unión a antigeno especificas para el componente amiloide serico p | |
| WO2016023898A3 (en) | Intracellular antigen binding | |
| PH12015502235A1 (en) | Sugar chain-polypeptide complex | |
| BR112015018035A2 (pt) | anticorpo anti-hmgb1 humanizado ou seu fragmento que se liga ao antígeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2743 DE 01-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |